{
    "nct_id": "NCT04895579",
    "official_title": "Boosting Immune Response With Copanlisib in Locally Advanced Unresectable Non-Small Cell Lung Cancer Receiving Durvalumab, A Phase Ib Study",
    "inclusion_criteria": "* Histologically confirmed NSCLC (e.g., adenocarcinoma, squamous cell) deemed unresectable or inoperable who have received concurrent chemoradiation.\n* Durvalumab will be started as consolidation therapy\n* Have at least one measurable lesion.\n* ECOG performance status ≤2.\n* Adequate organ and marrow function.\n* Ability to understand and the willingness to sign a written informed consent document.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Mixed Non-small cell and small cell histology; known EGFR and/or ALK driver mutations.\n* Treated with sequential chemoradiation therapy.\n* Autoimmune disease, such as rheumatoid arthritis, systemic lupus erythematosus, requiring systemic treatment with immunosuppressant in the past two years.\n* Patients who are receiving any other investigational agents orally or intravenously.\n* Systemic steroid for other purpose exceeding 10 mg prednisone a day except local injection at the discretion of the investigator.\n* Solid organ or bone marrow transplant recipients.\n* History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function.\n* Patients with uncontrolled inter-current illness.\n* Patients with psychiatric illness/social situations that would limit compliance with study requirements and patients with seizure disorder not well controlled.\n* Received live vaccine in the past 4 weeks.\n* Pregnant or breast-feeding/lactating women.\n* Receiving medications prohibited by the study.\n* New York Heart Association Class 3 or above.\n* Myocardial infarction within the last 6 months.\n* Unstable angina.\n* Venous thromboembolism within last 3 months.\n* Evidence or history of bleeding diathesis. Any hemorrhage or bleeding event ≥ CTCAE Grade 3 within 4 weeks.\n* Proteinuria of ≥ CTCAE Grade 3 or estimated by urine protein: creatinine ratio > 3.5\n* Major surgeries within the last 28 days.\n* Any illness or medical conditions that are unstable or could jeopardize the safety of patients and their compliance in the study.",
    "miscellaneous_criteria": ""
}